Bayer Acquires Perfuse for $2.45B in Ophthalmology; Novo Wegovy Pill Posts $355M Q1

Bayer is back in pharma M&A, putting up to two-point-four-five billion dollars behind Perfuse Therapeutics in what could be its largest drug company deal since 2020.

Novo's oral Wegovy just posted three-hundred-fifty-five million in first-quarter sales, two separate China-to-West deals topped a billion each, and Sanofi is voluntarily walking away from the FDA's embattled voucher program. Packed Wednesday.

Welcome to The Pharma Closeout for Wednesday, May sixth, twenty-twenty-six. I'm Alex Mercer.

And I'm Maya Patel. Let's get into it.

Three hundred million dollars upfront, up to two-point-four-five billion total including milestones. Bayer is acquiring Perfuse Therapeutics and its lead compound PER-001, a small molecule endothelin receptor antagonist in Phase 2 for glaucoma and diabetic retinopathy. Per BioPharma Dive, this is Bayer's first drug company acquisition in several years and potentially its largest since AskBio in 2020. The deal gives Bayer full rights to PER-001, pending antitrust clearance and stockholder approval.

The mechanism is what elevates this beyond a routine pipeline buy. ERAs are well characterized in pulmonary vascular disease, but applying them to ocular ischemia targets perfusion at the optic nerve head rather than intraocular pressure reduction. That's a fundamentally different therapeutic lane from current glaucoma standard of care, and if Phase 2 supports it, Bayer has a drug that sidesteps head-to-head competition with existing treatments entirely.

Let's bring in Marcus Webb for the deal structure. Marcus?

The strategic backdrop here is important. Ophthalmology has been one of the quietest corners of pharma M&A despite enormous patient populations. Bayer already has a commercial footprint in the eye space — they're not building a sales force or payer relationships from scratch. That changes the return math considerably.

The flip side is that ophthalmology M&A has been quiet for a reason. Fragmented prescriber base, complex payer dynamics, long adoption curves for novel mechanisms. Whether this deal catalyzes broader interest in the eye space hinges entirely on PER-001's Phase 2 data. That milestone structure reflects how much even Bayer is hedging against development risk.

Bayer wasn't the only one writing large checks today. Two major China-to-West transactions landed this morning. UCB is acquiring Candid Therapeutics for two-point-two billion dollars, bringing in a portfolio of bispecific antibodies that Candid licensed from China-based biotechs for autoimmune diseases. UCB calls it part of the next wave of immunological care.

The bispecific angle in autoimmunity is where the field is heading, but execution risk compounds fast. Bispecifics carry manufacturing complexity that conventional monoclonals don't, and that adds cost and timeline exposure to every milestone in this portfolio. At two-point-two billion, the margin for development setbacks is thin.

Separately, GSK paid fifty-five million upfront to license SA030 from China-based SiranBio, an ALK7-targeting siRNA for cardiometabolic disease, with milestones that could push the total to roughly one billion. That positions GSK directly in the lane Arrowhead Therapeutics has been building in obesity and metabolic space.

Two multi-hundred-million-dollar China-to-West deals on the same day is a pattern, not a coincidence. The licensing model for Chinese-origin assets has matured to the point where big pharma is deploying real capital — not option money — across therapeutic areas from autoimmune to cardiometabolic. The pipeline geography of this industry is shifting in real time.

Those pipeline bets make more sense when you see the commercial prize they're chasing. Novo Nordisk's oral Wegovy posted three-hundred-fifty-five million dollars in first-quarter sales. Total prescriptions showed robust uptake in Q1, marking the strongest GLP-1 launch by volume in the United States according to the company. Novo raised full-year guidance on the back of it.

The demand signal for non-injectable obesity treatment is now quantified, and it ran ahead of most models. For Lilly, this compresses the competitive window — Foundayo launched in April, but Novo already has three months of prescription momentum and a physician base writing comfortably for oral semaglutide. First-mover advantage in oral GLP-1 is real and measurable now.

Lilly's response on the supply side was its own headline — a substantial additional manufacturing investment across its Lebanon, Indiana sites, significantly expanding the company's total Indiana commitments since 2020.

Twenty-one billion in cumulative Indiana commitments since 2020. That isn't hedging. Companies don't pour that kind of capital into domestic capacity unless their internal models show durable, growing volume across years and across their portfolio. Lilly is building for a demand curve that doesn't plateau.

Rounding out the deal and data picture — Avalo Therapeutics scored a Phase 2 win in dermatology alongside a three-hundred-seventy-five million dollar raise. CellCentric raised two-hundred-twenty million for a multiple myeloma pill. Latus Bio secured ninety-seven million for a Huntington's gene therapy. Cytokinetics delivered positive data in a closely watched heart failure trial. Madrigal's MASH drug beat sales expectations. On the restructuring side, BioNTech is exiting several sites with a significant workforce impact, and Novartis announced job cuts while closing a German facility. Biotech as a subsector was up two-point-four-nine percent on the session, while medical distribution dropped eight-point-seven-eight percent — a sharp outlier decline. The breadth of today's activity — ophthalmology, autoimmune, metabolic, cardiology — shows capital chasing pipeline assets across every major therapeutic lane simultaneously.

All that capital deployment assumes a stable regulatory and pricing environment. And today raised questions about both. Sanofi asked the FDA to withdraw its Tzield label expansion from the Competitive New Product Voucher program. The CNPV has been dogged by missed deadlines and transparency concerns since its launch, with earlier reports of FDA-delayed reviews within the program tied to safety signals. A company voluntarily stepping out of a program designed to accelerate review is a notable signal about how the industry is reassessing the program's risk-benefit calculus.

If the CNPV pathway is introducing review uncertainty rather than reducing it, a standard timeline with predictable milestones may actually be the faster and cleaner route. The fact that Sanofi made this decision publicly says something about where confidence in the program stands — and whether other applicants start doing the same math.

On pricing, the White House put out a number today — five-hundred-twenty-nine billion in projected savings over ten years from the Most Favored Nation model. That figure will be debated, but the near-term reality is already showing up in earnings. Both Amgen and AbbVie flagged IRA negotiation effects on first-quarter sales. The pricing overhang is migrating from policy debate to income-statement impact faster than most models assumed.

Also worth noting — the FDA launched a one-day facility assessment pilot to complement standard inspections. If it scales, it could reduce manufacturing-related approval bottlenecks. And separately, the New York Times reported that the FDA has blocked publication of vaccine safety studies — a development worth monitoring for broader regulatory transparency implications.

Between the CNPV withdrawal, the MFN projections, and the inspection pilot, the regulatory and pricing environment is being actively reshaped. Companies aren't waiting for final rules — they're repositioning quarter by quarter, and investors should expect that cadence to continue.

Looking ahead, the near-term catalyst is a May tenth PDUFA date for Argenx's VYVGART in seronegative generalized myasthenia gravis — a positive decision would considerably widen the drug's addressable population. And with both Amgen and AbbVie flagging IRA impacts on Q1, the next round of pharma earnings calls will be closely parsed for how pricing negotiations are flowing through to full-year guidance.

On the data side, Viridian's new Phase 3 results in chronic thyroid eye disease are being repriced by analysts as far more competitive with Amgen's Tepezza than earlier findings suggested. And ahead of ASCO, Celcuity has breast cancer data that could support a broader filing. Conference season is about to accelerate, and several upcoming readouts will reshape competitive assumptions across oncology and autoimmune. Watch the data, not just the headlines.

That is your Pharma Closeout for Wednesday. Bayer back in the M&A game with a two-point-four-five billion dollar ophthalmology play, Novo's oral Wegovy off to a scorching start, two billion-dollar-plus China-to-West deals reshaping the pipeline map, and Sanofi walking away from the CNPV program entirely. This industry does not take days off. If this briefing saves you time, follow us on Spotify and drop a rating — we're back tomorrow.

Enjoy your evening, everyone. See you tomorrow.